Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
BASKING RIDGE, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) ("Lisata" or the "Company"), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that management will participate in the following events in June:
新澤西州巴斯金裏奇，2024年5月28日（GLOBE NEWSWIRE）——開發治療晚期實體瘤和其他嚴重疾病的創新療法的臨床階段製藥公司Lisata Therapeutics, Inc.（納斯達克股票代碼：LSTA）（“Lisata” 或 “公司”）今天宣佈，管理層將在6月參加以下活動：
BIO International Convention (June 3-6, 2024)
Format: In-person
Location: San Diego, California
Presentation Date: Monday, June 3, 2024
Presentation Time: 2:15 p.m. Pacific Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
BIO 國際大會（2024 年 6 月 3 日至 6 日）
格式：面對面
地點：加利福尼亞州聖地亞哥
演講日期：2024 年 6 月 3 日，星期一
演講時間：太平洋時間下午 2:15
主持人：大衛·馬佐博士，Lisata總裁兼首席執行官
Management will be available for one-on-one meetings with registered attendees. To schedule a meeting with the Company, please reach out to the Lisata representative under the contact section below or through the conference platform. For more information on the event, please visit https://convention.bio.org/.
管理層將可以與註冊與會者進行一對一的會議。要安排與公司的會面，請在下面的聯繫部分下或通過會議平台與Lisata代表聯繫。有關該活動的更多信息，請訪問 https://convention.bio.org/。
GCFF 2024 Bio Investing Conference
Format: Virtual
Presentation Date: Thursday, June 20, 2024
Presentation Time: 10:00 a.m. Pacific Time
Presenter: David J. Mazzo, PhD, President and Chief Executive Officer of Lisata
GCFF 2024 生物投資會議
格式：虛擬
演講日期：2024 年 6 月 20 日星期四
演講時間：太平洋時間上午 10:00
主持人：大衛·馬佐博士，Lisata總裁兼首席執行官
For more information on the conference and how to register, please visit https://www.eventbrite.ca/e/gcff-virtual-2024-bio-investing-conference-tickets-905051061087?aff=LSTA.
About Lisata Therapeutics
關於 Lisata Therapeu
Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata's lead product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. For more information on the Company, please visit www.lisata.com.
Lisata Therapeutics 是 處於臨床階段的製藥公司 致力於發現、開發和商業化治療晚期實體瘤和其他主要疾病的創新療法。Lisata的主要候選產品， certepetide（原名 LSTA1），是一種在研藥物，旨在激活一種新的攝取途徑，該途徑允許共同給藥或聯用抗癌藥物選擇性地靶向和更有效地穿透實體瘤。Lisata已經在其基礎上建立了值得注意的商業和研發合作伙伴關係 cENDR 平台 技術。該公司預計將在未來兩年內宣佈衆多里程碑，並相信其預計資本將爲2026年初的運營提供資金，其中包括正在進行和計劃中的臨床試驗的預期數據里程碑。有關該公司的更多信息，請訪問 www.lisata.com。
Contact:
聯繫人：
Investors:
投資者：
Lisata Therapeutics, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone: 908-842-0084
Email: jmenditto@lisata.com
Lisata Therapeutics, In
約翰·門迪託
投資者關係和企業傳播副總裁
電話：908-842-0084
電子郵件：jmenditto@lisata.com
Media:
媒體：
ICR Westwicke
Elizabeth Coleman
Senior Associate
Phone: 203-682-4783
Email: elizabeth.coleman@westwicke.com
ICR Westwicke
伊麗莎白·科爾曼
高級助理
電話：203-682-4783
電子郵件：elizabeth.coleman@westwicke.com
譯文內容由第三人軟體翻譯。